Marcucci 2005.

Methods	Randomised DBPC trial
Participants	Children Active 13 (6 m); losses to f/u 0 Placebo 11 (10m); losses to f/u 0
Interventions	12 months SLIT Sublingual drops Maintenance dose: 0.8 mcg of mite allergen group 1 and 0.4 mcg of mite allergen group 2
Outcomes	Symptom scores for rhinitis and asthma Medication scores Nasal tryptase Nasal IgE Specific nasal challenge test Nasal ECP Sputum ECP Sputum tryptase Serum IgE
Notes	Jadad scale 5/5
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	Patients were randomised, but no details about randomisation provided
Allocation concealment?	Unclear risk	No details were provided
Blinding? All outcomes	Low risk	The placebo preparation was identical to active treatment in terms of composition, appearance, presentation, taste and colour, but did not contain allergens
Incomplete outcome data addressed? All outcomes	Low risk	Participants excluded were accounted for along with patients followed to designated follow‐up periods
Free of selective reporting?	Low risk	The specified outcomes in the methodology were reported in the results section
Free of other bias?	Low risk	No other sources of bias were detected or suspected